Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives $4.50 Average Target Price from Brokerages

Heron Therapeutics, Inc. (NASDAQ:HRTX) has earned an average rating of “Hold” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $4.50.

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Heron Therapeutics in a research note on Friday, January 9th. Zacks Research raised shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Thursday, January 22nd.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Rubric Capital Management LP lifted its position in shares of Heron Therapeutics by 3.3% during the 4th quarter. Rubric Capital Management LP now owns 30,046,828 shares of the biotechnology company’s stock worth $39,061,000 after buying an additional 946,100 shares during the period. Clearline Capital LP raised its stake in Heron Therapeutics by 26.0% during the fourth quarter. Clearline Capital LP now owns 12,235,239 shares of the biotechnology company’s stock worth $15,906,000 after acquiring an additional 2,522,712 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Heron Therapeutics by 9.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 11,185,325 shares of the biotechnology company’s stock worth $14,541,000 after acquiring an additional 946,100 shares in the last quarter. Velan Capital Investment Management LP lifted its holdings in shares of Heron Therapeutics by 25.3% during the third quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock valued at $11,029,000 after acquiring an additional 1,766,546 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Heron Therapeutics by 2,785.2% during the fourth quarter. Millennium Management LLC now owns 7,169,908 shares of the biotechnology company’s stock valued at $9,321,000 after acquiring an additional 6,921,405 shares during the period. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

HRTX stock opened at $0.80 on Friday. Heron Therapeutics has a twelve month low of $0.74 and a twelve month high of $2.61. The company has a market cap of $150.68 million, a PE ratio of -6.15 and a beta of 1.42. The business’s 50-day simple moving average is $1.07 and its 200 day simple moving average is $1.19. The company has a quick ratio of 1.51, a current ratio of 2.48 and a debt-to-equity ratio of 10.59.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $40.59 million during the quarter, compared to analyst estimates of $39.53 million. On average, research analysts anticipate that Heron Therapeutics will post -0.13 earnings per share for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.